Related Experiment Videos
Novel therapeutic agents for systemic lupus erythematosus
1Division of Rheumatology, University of California, San Francisco 94143, USA.
Current Opinion in Rheumatology
|August 23, 2002
Summary
New therapies offer hope for systemic lupus erythematosus (SLE) treatment, moving beyond traditional immunosuppressants. This review explores novel immunosuppressants, biologics, and immunoablation techniques for managing SLE and lupus nephritis.
Area of Science:
- Immunology
- Oncology
- Endocrinology
Background:
- The last major advancement in systemic lupus erythematosus (SLE) treatment involved cyclophosphamide and methylprednisolone for lupus nephritis.
- Recent progress in immunology, oncology, and endocrinology has yielded numerous potential SLE therapies.
Purpose of the Study:
- To review emerging therapies for systemic lupus erythematosus (SLE).
- To discuss novel treatment strategies including immunosuppressants, biologics, tolerizing agents, immunoablation, and hormonal medications.
Main Methods:
- Review of current literature on SLE treatment advances.
- Discussion of therapies in clinical practice and those in early-stage trials.
- Categorization of therapies based on their mechanism of action (specific vs. nonspecific immune inhibition).
Main Results:
- Identified several new therapeutic classes for SLE, including novel immunosuppressants and biologic medications.
- Highlighted therapies currently in use, such as mycophenolate mofetil, and those in development, like anti-BLyS monoclonal antibodies.
- Distinguished between targeted therapies (e.g., anti-CD40L monoclonal antibody) and broadly acting ones (e.g., immunoablation).
Conclusions:
- Multiple novel therapeutic avenues are emerging for SLE treatment.
- These advancements offer potential for more effective and targeted management of SLE and its complications.
- The review provides an overview of the evolving landscape of SLE therapeutics.